HDAC9 and neoplasm: Our upstream analyses had indicated that TNBC tumor specimens expressed higher levels of HDACs which, in turn, curtails PPARγ-mediated anticancer signaling pathways, suggesting that HDAC inhibition may be required to reverse the brakes on PPARγ-mediated anticancer effects.